CONCLUSIONS: These findings reveal a previously unrecognized regulatory axis controlling HLA-II expression on cancer cells, suggesting that targeting the AHR-ARNT pathway may enhance tumor immunogenicity and improve immunotherapy efficacy. The gene discussed is AHR; the disease is cancer.